Nvidia stock slips as Intel filing confirms $5 billion stake — here’s what’s next
29 December 2025
1 min read

Nvidia stock slips as Intel filing confirms $5 billion stake — here’s what’s next

NEW YORK, December 29, 2025, 09:35 ET — Regular session

  • Nvidia shares fell about 1.4% in early trading after a filing detailed its completed $5 billion investment in Intel. 1
  • Intel said it issued 214.8 million shares to Nvidia at $23.28 per share in a private placement that closed on Dec. 26. 2
  • Investors are watching thin year-end trading, upcoming Fed minutes, and Nvidia’s next earnings on Feb. 25. 3

Nvidia shares were down about 1.4% at $187.92 in early U.S. trading on Monday after Intel disclosed details of a $5 billion share sale to the AI chipmaker. 1

The disclosure matters now because it confirms the cash outlay and turns a headline September agreement into an executed equity stake, even as investors reassess big-cap tech positions into year-end. 2

It also puts a fresh spotlight on Nvidia’s capital allocation and on its strategic ties with Intel at a time when chip stocks have been a major driver of U.S. equity gains this year. 3

Intel said in a Form 8-K — a U.S. securities filing used to report significant corporate events — that it completed the issuance and sale of 214,776,632 shares to Nvidia on Dec. 26 for $5.0 billion in cash, or $23.28 per share. 2

The company said the shares were sold in a private placement, meaning they were issued directly to an investor rather than offered to the public market. 2

Reuters reported earlier that U.S. antitrust authorities had cleared Nvidia’s investment in Intel, after the Federal Trade Commission posted a notice earlier this month. 4

Intel shares were little changed in early trading, while Nvidia extended a pullback that began in premarket moves across several AI-linked names. 4

The agreed price of $23.28 per Intel share sits well below Intel’s trading level around $36 on Monday, underlining how far Intel has rallied since the pact was announced. 2

Nvidia’s stock is up about 42% so far this year, but it has been sensitive to shifts in risk appetite and valuation concerns in the final stretch of 2025. 1

More broadly, Wall Street’s main indexes were set to start the final week of the year on a softer note, with trading expected to be light and U.S. markets shut on Thursday for New Year’s Day. 3

On the macro calendar, minutes from the Federal Reserve’s previous meeting and the weekly jobless claims report are among the main scheduled data points this week. 3

Some investors are also parsing separate AI-infrastructure dealmaking around Nvidia’s ecosystem. Bernstein Research analyst Stacy Rasgon wrote that one licensing-style structure “could ‘keep the fiction of competition alive’,” according to Axios. 5

For Nvidia-specific catalysts, the next big scheduled event is its fourth-quarter fiscal 2026 financial results on Feb. 25, according to the company’s investor calendar. 6

Until then, traders are likely to watch whether the Intel stake triggers follow-on disclosures and whether the broader “AI-linked” trade stabilizes as liquidity thins into the holiday. 2

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Firefly Aerospace stock steadies in premarket as lawsuit notice puts spotlight back on IPO claims
Previous Story

Firefly Aerospace stock steadies in premarket as lawsuit notice puts spotlight back on IPO claims

Apple stock slips early as year-end tech rally cools, with China demand in focus
Next Story

Apple stock slips early as year-end tech rally cools, with China demand in focus

Go toTop